Eurocine Vaccines finances further development

Eurocine Vaccines´ board of directors has decided, with the support of the authorization from the AGM on 21 December 2021, to carry out a fully guaranteed preferential share issue, with subscription period 4 – 18 October 2022. The company has published an Information Memorandum at Investors – Eurocine Vaccines (, which contains complete conditions and instructions. Subscription forms and a Summary Teaser will be available at Investors – Eurocine Vaccines ( during the subscription period.

Nordic Issuing’s website ( also offers the option to subscribe for shares via digital signature.